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Abstract B cells are increasingly coming into play in the pathogenesis of multiple sclerosis (MS).
Here, we screened peripheral bloodmononuclear cells (PBMC) from patients with clinically isolated
syndrome (CIS), MS, other non-inflammatory neurological, inflammatory neurological or autoim-
mune diseases, and healthy donors for their B cell reactivity to CNS antigen using the enzyme-linked
immunospot technique (ELISPOT) after 96 h of polyclonal stimulation. Our data show that nine of 15
patients with CIS (60.0%) and 53 of 67 patients with definite MS (79.1%) displayed CNS-reactive B
cells, compared to none of the control donors. The presence of CNS-reactive B cells in the blood of
themajority of patients withMS or at risk to develop MS alongwith their absence in control subjects
suggests that they might be indicative of a B cell-dependent subpopulation of the disease.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC
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21Identification of a B cell-dependent subpopulation of multiple sclerosis1. Introduction accompanying systemic or psychiatric disorders. SubjectsMultiple sclerosis (MS) affects approximately 2.5 million
people worldwide and is one of the most common causes of
nontraumatic disability among young and middle-aged people
[1–3]. MS has remained a diagnosis of exclusion since even the
integration of a multitude of findings related to MS does not
provide a diagnosis with certainty [2,3]. The etiology of MS is
presently unknown. MS is considered to be an autoimmune
disorder. This concept is supported by animal models, in which
immunization with central nervous system (CNS) antigens
causes a disease that shares features of MS [4], and by the
histopathology of MS lesions that show inflammatory infil-
trates and signs of immune-mediated pathology [5,6]. The
autoantigens that have been implicated in the autoimmune
hypothesis of MS are mainly myelin proteins such as myelin
basic protein (MBP), proteolipid protein (PLP) and myelin
oligodendrocyte glycoprotein (MOG) [7]. Recently, antibod-
ies against the potassium channel KIR4.1 have been
identified [8].
In the past, there have been difficulties to detect B cell
autoimmunity to CNS antigens in MS patients [9,10]. These
difficulties might have resulted from attempts to test for
serum antibodies alone, rather than including B cells them-
selves. Autoantibodies are prone to be absorbed in the target
organ, evading their detection in the serum. B cells that
produce antibodies in vivo are primarily located in the bone
marrow and, in cases of antigen-induced inflammation, locally
at the sites where the antigen is present or in the draining
lymphoid tissues. While B cells recirculate in the body, those
trafficking in the blood are typically resting lymphocytes that
do not produce antibodies. When stimulated with suitable
mitogens in vitro, however, these in vivo resting B cells
convert into antibody-producing plasma cells [11] whose
antigen specificity can be measured using the enzyme-linked
immunospot technique (ELISPOT). In B cell ELISPOT assays the
membrane is coated with the antigen(s) of interest and
antigen-specific antibodies are captured around the B cells
that secrete those antibodies. Increased frequencies of
antigen-specific B cells indicate that the cells have undergone
clonal expansion during an immune response. In addition, the
production of antibodies other than IgM suggests that the B
cells are memory cells that have undergone T cell-dependent
immunoglobulin class switching. Therefore, the detection of
increased frequencies of non-IgM producing CNS antigen-
specific B cells in the blood of patients with clinically isolated
syndrome (CIS) or MS implies that these patients display an
active CNS antigen-specific autoimmune T and B cell
response.
In the following, we set out to test the hypothesis that
CNS-specific B cells are regularly clonally expanded and
isotype-switched in CIS and MS patients, providing a diagnostic
marker for B cell-dependent disease.
2. Material and methods
2.1. Subjects
Patients with CIS/MS were diagnosed according to the 2005
or 2010 McDonald criteria, respectively. Exclusion criteria
were a history of other autoimmune diseases and severewho had undergone plasmapheresis or received anti-B cell
therapy, intravenous immunoglobulin or immunosuppressive
treatment 12 months prior to inclusion in the study were
also excluded. The control groups consisted of healthy
donors (HD) (n = 127), patients with non-inflammatory
neurological diseases other than MS (OND) (n = 12), other
inflammatory neurological diseases (OIND) (n = 16) and
other autoimmune diseases (OAUT) (n = 13). Details on all
cohorts are provided in Table 1. The HD, OIND and OAUT
cohorts were age- and gender-matched to the CIS/MS
cohort. The research protocol was approved by the relevant
institutional ethics committee. All human participants gave
written informed consent. All patients and 42 healthy
donors were recruited from the University Hospitals of
Cologne.2.2. ELISPOT
PBMC were isolated from the blood by Ficoll-Paque (GE
Healthcare Europe GmbH, Freiburg, Germany) density
gradient centrifugation. Eighty-five healthy control samples
were obtained as ePBMC® from Cellular Technology Limited
(Shaker Heights, OH, USA). The people performing the assay
were blinded for the samples. The PBMC samples were
comparable with respect to the number of dead cells and B
cells as confirmed by acridine orange/ethidium bromide
staining and flow cytometry. For polyclonal stimulation of B
cells, PBMC were cultured for 96 h prior to the ELISPOT assay
at a concentration of 3 × 106 cells/ml in complete RPMI-1640
medium that was supplemented with R-848 at 2.5 μg/ml
(Enzo Life Sciences, Inc., Farmingdale, NY), IL-2 at 0.1 μg/ml
(Peprotech, Hamburg, Germany) and 0.0143 mol/L
β-mercaptoethanol (Sigma, Schnelldorf, Germany). Poly-
clonal stimulation with R-848 and IL-2 has previously been
shown to be a simple method for the selective activation of
memory B cells [11].
Complete RPMI medium consisted of RPMI-1640 (Lonza,
Cologne, Germany) containing 10% FBS (Biochrom), 1% L-
glutamine (Sigma) and 1% penicillin/streptomycin (Sigma).
The plates were coated overnight with whole human brain
lysate which was isolated from fresh frozen tissue (30 μg/ml;
Novus Biologicals, Littleton, CO). Coating with anti-human Igκ
at 10 μg/ml served as a positive control. Plates were blocked
with 10% FBS in sterile PBS for 2 h at room temperature. Each
sample was plated in duplicates with 1 million polyclonally
stimulated PBMC per well, which we found to be the optimal
cell concentration in titration experiments. All plates were
developed with CTL True Blue substrate. Spots were counted
on an ImmunoSpot® Series 6 Analyzer.2.3. Statistical analysis
PBMC samples were considered positive when the number of
CNS-specific ELISPOTs was at least 3 SD above the mean
value of the healthy donors. ELISPOT results were compared
between the test subject groups with the use of the
Kruskal–Wallis-Test followed by Dunn's correction. P-values
of less than 0.05 were considered to indicate statistical
significance.
Table 1 Study characteristics of the donor cohorts tested by ELISPOT.
Variable Healthy controls OND a OIND b OAUT c CIS MS
No. of donors 127 12 16 13 15 67
Female sex 55 6 8 7 9 40
No (%) (43.3) (50.0) (50.0) (53.8) (60.0) (59.7)
Age—yrs 37.8 ± 11.0 d 64.3 ± 12.9 49.3 ± 17.8 42.3 ± 14.3 36.1 ± 9.8 39.0 ± 9.8
(18–64) (32–78) (20–80) (22–74) (21–53) (18–58)
EDSS n.a. n.a. n.a. n.a. 1.2 ± 1.0 2.3 ± 1.5
(0–3.5) (0–6.5)
ELISPOT
Positive
—no. (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 9 (60.0) 53 (79.1)
Abbreviations: CIS = clinically isolated syndrome; EDSS = expanded disability status scale; MS = multiple sclerosis; OAUT = other autoimmune
diseases; OIND = other inflammatory neurological diseases; OND = other non-inflammatory neurological diseases.
a The OND cohort comprised five patients with stroke, one patient with a restless leg syndrome, one patient with epilepsia, one patient
with a cerebral venous sinus thrombosis, one patient with stenosis of the basilar artery, one patient with retrograde amnesia, one patient
with polymyositis and one patient with unclear cerebral lesions.
b The OIND cohort comprised four patients with viral meningitis, six patients with Parkinson's disease, one patient with neuroborreliosis,
one patient with cerebral toxoplasmosis, one patient with myelitis, two patients with optic neuritis and one patient with leucoclastic
vasculitis.
c The OAUT cohort comprised two patients with systemic lupus erythematodes, three patients with diabetes type I, one patient with psoriasis,
one patient with sclerodermia, two patients with ulcerative colitis, one patient with Wegener's granulomatosis, one patient with Hashimoto's
thyreoiditis and one patient with rheumatoid arthritis.
d Mean values ± SD are shown.
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PBMC were isolated from healthy donors, CIS and MS patients
as well as from patients with other non-inflammatory
neurological, other inflammatory neurological or other
autoimmune diseases (Table 1) and polyclonally stimulated
with R-848, IL-2 and β-mercaptoethanol for 96 h, during
which resting B cells convert into antibody producing plasma
cells [11]. As shown in Fig. 1 none of the healthy controls
(n = 127) or OND (n = 12), OIND (n = 16) and OAUT (n = 13)
patients showed increased numbers of CNS-specific B cells in
the blood exceeding 1 in 106 among the stimulated PBMC
being the lower detection limit of the assay. In contrast, 9 of
15 patients with CIS (60.0) and 53 of 67 patients with MS
(79.1%) showed numbers between 4.5 and 150 CNS-specific B
cells (Figs. 1A,B). Subdividing the MS cohort into disease
subtypes, 48 of 60 (80.0%) with relapsing–remitting and 5 of
7 (71.4%) patients with secondary progressive MS displayed a
positive CNS-specific B cell response. The CNS-specific B cell
response was retested in 20 MS patients 6 months later.
Results are displayed in Fig. 1C and delineate the reproduc-
ibility of the data. In the majority of patients (16 of 20) the
CNS-specific B cell response was comparable at the two time
points tested. Four patients that had tested negative
initially showed a positive response after six months
suggesting that a conversion to B cell-dependent MS can
occur in the course of the disease. The number of CNS-
specific B cell positive CIS and MS patients was independent
of the treatment status. Ten of 15 CIS patients were treated
either with IFN-β or glatirameracetate, while five patients
were untreated. In the MS cohort, 39 patients received
either IFN-β or glatirameracetate, 18 patients were treated
with natalizumab, two patients with mitoxantrone, onepatient with fingolimod and seven patients were untreated
at the time point of testing.
4. Discussion
Here we tested polyclonally stimulated B cells from patients
with CIS/MS for their reactivity to CNS antigens. Our data
suggest that CNS-specific B cells are associated with the
development of MS. These results fit well into the recently
emerging concept of a major contribution of B cells to the
immune pathogenesis of MS [12]. In MS lesions antibody and
complement depositions are frequently observed and represent
the most prominent pattern of demyelination [5]. Oligoclonal
bands are thought to reflect active B cell immunity both in the
CNS itself and in the peripheral blood [13]. Much attention has
recently been drawn to the occurrence of B cell-rich lymphoid
structures in the brains of MS patients [14,15]. The therapeutic
success achieved by depleting B cells with the antibodies
rituximab [16], alemtuzumab [17] or ofatumumab [18] and by
the reduction of endogenous antibody levels by plasmapheresis
[19] further supports the pathogenic role of B cells in MS. In
addition, it has been shown that the memory B cell pool from
patients with MS encompassed both MOG- and MBP-reactive B
cells that could activate T cells [20]. However, there is also a
subpopulation of MS patients in which antibody depositions
are absent within CNS lesions [5] suggesting that the disease
may occur in a B cell/antibody-dependent versus -independent
subtype. In our study we found MS patients with and without
brain-reactive B cells in their blood. It is conceivable that the
detection of CNS-specific B cells in the PBMC population allows
the identification of B cell-dependent MS patients, who would
benefit from early B cell-targeted therapy. The number of
patients showing a B cell response to CNS antigen was lower in
Figure 1 CNS-specific B cells in the CIS/MS patient subpopulation. PBMC were obtained from 127 healthy donors (HD), 12 patients
with other neurological diseases (OND), 16 patients with other inflammatory neurological diseases (OIND), 13 patients with other
autoimmune diseases (OAUT), 15 patients with a clinically isolated syndrome (CIS) and 67 multiple sclerosis (MS) patients. The
production of CNS-specific antibodies was measured on CNS antigen-coated ELISPOT plates. One million PBMC were plated after 96 h
of polyclonal B cell stimulation with R-848, IL-2 and β-mercaptoethanol. (A) Representative ELISPOT well images of polyclonally
stimulated B cells from HD, O(I)ND/OAUT and CIS/MS patients are shown. (B) The numbers of CNS-specific B cells in the polyclonally
stimulated PBMC population are shown for each individual donor in the specified groups. The hatched line delineates the cut-off value
for a positive response as calculated from the mean spot number + 3 SD of the HD group. Background (medium alone) was subtracted
from the results. The background was typically b5% of the antigen response. (C) Twenty donors were retested 6 months later. The
results for the individual donors are displayed. The symbol at 150 refers to a patient with a CNS-specific B cell response that classified
as “too numerous to count”, which was thus set to the maximum of 150. Background (medium alone) was subtracted from the results.
The background was typically b5% of the antigen response. The stability of the ELISPOT assay was confirmed by pre-testing of healthy
donors for cytomegalovirus (CMV) antigen after polyclonal stimulation at different time points using identical PBMC samples.
23Identification of a B cell-dependent subpopulation of multiple sclerosispatients with CIS compared toMS. The reason for this difference
between the two groups might reside in the establishment of a
pathogenic B cell component and the occurrence of antigen
spreading only in the course of the disease. Accordingly, only
the fraction of CIS patients that is prone to develop MS will
eventually develop CNS-specific B cells. Clearly, follow-up
multi-center studies are needed to confirm this notion and also
to evaluate whether measurements of CNS-specific B cells are
of predictive and therapeutic value. The present data derived
from a single MS center still have to be corroborated in
extended cohorts from diverse countries to also control for
geographic, ethnical, and environmental factors. In our study
we deliberately chose CNS lysate as antigenic target taking into
account that each individual patient recognizes a multitude of
different tissue antigens. In our opinion, the use of single
antigens would have been counterintuitive also following the
epitope spreading hypothesis ofMS. Therefore, and in particular
from a clinical point of view the approach presented here
should be the most feasible.
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